scholarly journals Medical and non‐medical cannabis use and risk of prescription opioid use disorder: Findings from propensity score matching

2019 ◽  
Vol 38 (6) ◽  
pp. 597-605 ◽  
Author(s):  
Di Liang ◽  
Mark S. Wallace ◽  
Yuyan Shi
Keyword(s):  
Propensity Score ◽  
Propensity Score Matching ◽  
Opioid Use Disorder ◽  
Cannabis Use ◽  
Prescription Opioid ◽  
Medical Cannabis ◽  
Opioid Use ◽  
Prescription Opioid Use

scholarly journals Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States

2018 ◽  
Vol 175 (1) ◽  
pp. 47-53 ◽  
Author(s):  
Mark Olfson ◽  
Melanie M. Wall ◽  
Shang-Min Liu ◽  
Carlos Blanco
Keyword(s):  
United States ◽  
The United States ◽  
Opioid Use Disorder ◽  
Cannabis Use ◽  
Prescription Opioid ◽  
Opioid Use ◽  
Prescription Opioid Use

scholarly journals Comparing Cannabis Use Across Diagnosed Conditions: Apples and Oranges?

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 510-511
Author(s):  
Brian Kaskie
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Social Activity ◽  
Well Being ◽  
Cannabis Use ◽  
Prescription Opioid ◽  
Medical Cannabis ◽  
Opioid Use ◽  
Prescription Opioid Use

Abstract Although researchers have identified medications that relieve symptoms of Multiple Sclerosis (MS), none are entirely effective and some persons with multiple sclerosis (PwMS) use alternatives. Our study compared cannabis use among PwMS (N=135) and persons diagnosed with arthritis (N=582) or cancer (N=622) who participated in the Illinois medical cannabis program. We tested for significant differences across psychological well-being, quality of life and three behavioral outcomes, and also considered effects of co-occurring prescription opioid use. A majority of all individuals used cannabis to address pain and improve quality of sleep. PwMS reported lower levels of productivity, exercise and social activity, and cannabis was less helpful with improving these particular outcomes. Most persons used cannabis for sleep or digestive problems and we found no differences across groups in terms of well-being and quality of life. This comparative evaluation suggests cannabis mechanisms are not specific as much as they impact common processes.

Opioid tapering in patients with prescription opioid use disorder: A retrospective study

2017 ◽  
Vol 17 (1) ◽  
pp. 167-173 ◽  
Author(s):  
Kehua Zhou ◽  
Peng Jia ◽  
Swati Bhargava ◽  
Yong Zhang ◽  
Taslima Reza ◽  
...  
Keyword(s):  
Trigger Point ◽  
Retrospective Chart Review ◽  
Opioid Use Disorder ◽  
Prescription Opioid ◽  
Office Visits ◽  
Opioid Use ◽  
Clinical Practices ◽  
Medication Assisted Treatment ◽  
Opioid Tapering ◽  
Prescription Opioid Use

AbstractBackground and aimsOpioid use disorder (OUD) refers to a maladaptive pattern of opioid use leading to clinically significant impairment or distress. OUD causes, and vice versa, misuses and abuse of opioid medications. Clinicians face daily challenges to treat patients with prescription opioid use disorder. An evidence-based management for people who are already addicted to opioids has been identified as the national priority in the US; however, options are limited in clinical practices. In this study, we aimed to explore the success rate and important adjuvant medications in the medication assisted treatment with temporary use of methadone for opioid discontinuation in patients with prescription OUD.MethodsThis is a retrospective chart review performed at a private physician office for physical medicine and rehabilitation. We reviewed all medical records dated between December 1st, 2011 and August 30th, 2016. The initial evaluation of the included patients (N =140) was completed between December 1st, 2011 and December 31st, 2014. They all have concumittant prescription OUD and chronic non-cancer pain. The patients (87 female and 53 male) were 46.7 ± 12.7 years old, and had a history of opioid use of 7.7 ±6.1 years. All patients received the comprehensive opioid taper treatments (including interventional pain management techniques, psychotherapy, acupuncture, physical modalities and exercises, and adjuvant medications) on top of the medication assisted treatment using methadone (transient use). Opioid tapering was considered successful when no opioid medication was used in the last patient visit.ResultsThe 140 patients had pain of 9.6 ± 8.4 years with 8/10 intensity before treatment which decreased after treatment in all comparisons (p < 0.001 for all). Opioids were successfully tapered off in 39 (27.9%) patients after 6.6 ±6.7 visits over 8.8 ±7.2 months; these patients maintained opioid abstinence over 14.3 ± 13.0 months with regular office visits. Among the 101 patients with unsuccessful opioid tapering, 13 patients only visited the outpatient clinic once. Significant differences were found between patients with and without successful opioid tapering in treatment duration, number of clinic visits, the use of mirtazepine, bupropion, topiramate, and trigger point injections with the univariate analyses. The use of mirtazepine (OR, 3.75; 95% CI, 1.48–9.49), topiramate (OR, 5.61; 95% CI, 1.91–16.48), or bupropion (OR, 2.5; 95% CI, 1.08–5.81) was significantly associated with successful opioid tapering. The associations remain significant for mirtazepine and topiramate (not bupropion) in different adjusted models.ConclusionsWith comprehensive treatments, 27.9% of patients had successful opioid tapering with opioid abstinence for over a year. The use of mirtazepine, topiramate, or likely bupropion was associated with successful opioid tapering in the medication assisted treatment with temporary use of methadone. Opioid tapering may be a practical option and should be considered for managing prescription OUD.ImplicationsFor patients with OUD, indefinite opioid maintenance treatment may not be necessary. Considering the ethical values of autonomy, nonmaleficence, and beneficence, clinicians should provide patients with OUD the option of opioid tapering.

scholarly journals Social Stigma Toward Persons With Prescription Opioid Use Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies

2017 ◽  
Vol 68 (5) ◽  
pp. 462-469 ◽  
Author(s):  
Alene Kennedy-Hendricks ◽  
Colleen L. Barry ◽  
Sarah E. Gollust ◽  
Margaret E. Ensminger ◽  
Margaret S. Chisolm ◽  
...  
Keyword(s):  
Public Health ◽  
Social Stigma ◽  
Public Support ◽  
Opioid Use Disorder ◽  
Prescription Opioid ◽  
Opioid Use ◽  
Prescription Opioid Use

scholarly journals Targeting the Orexin System for Prescription Opioid Use Disorder

2020 ◽  
Vol 10 (4) ◽  
pp. 226 ◽  
Author(s):  
Alessandra Matzeu ◽  
Rémi Martin-Fardon
Keyword(s):  
Opioid Use Disorder ◽  
Prescription Opioid ◽  
Prescription Opioids ◽  
Opioid Use ◽  
Effective Strategies ◽  
System A ◽  
Clinical Pain ◽  
Promising Target ◽  
Nonmedical Use ◽  
Prescription Opioid Use

Prescription opioids are potent analgesics that are used for clinical pain management. However, the nonmedical use of these medications has emerged as a major concern because of dramatic increases in abuse and overdose. Therefore, effective strategies to prevent prescription opioid use disorder are urgently needed. The orexin system has been implicated in the regulation of motivation, arousal, and stress, making this system a promising target for the treatment of substance use disorder. This review discusses recent preclinical studies that suggest that orexin receptor blockade could be beneficial for the treatment of prescription opioid use disorder.

scholarly journals Treatment of Prescription Opioid Use Disorder in Pregnant Women

2017 ◽  
Vol 174 (3) ◽  
pp. 208-214 ◽  
Author(s):  
Constance Guille ◽  
Kelly S. Barth ◽  
Julio Mateus ◽  
Jenna L. McCauley ◽  
Kathleen T. Brady
Keyword(s):  
Pregnant Women ◽  
Opioid Use Disorder ◽  
Prescription Opioid ◽  
Opioid Use ◽  
Prescription Opioid Use
Sign in / Sign up

Export Citation Format

Share Document